BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 McDuffie D, Barr D, Helm M, Baumert T, Agarwal A, Thomas E. Physiomimetic In Vitro Human Models for Viral Infection in the Liver. Semin Liver Dis 2023;43:31-49. [PMID: 36402129 DOI: 10.1055/a-1981-5944] [Reference Citation Analysis]
2 Floreani A, Bizzaro D, Shalaby S, Taliani G, Burra P; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Sex disparity and drug-induced liver injury. Dig Liver Dis 2023;55:21-8. [PMID: 35843842 DOI: 10.1016/j.dld.2022.06.025] [Reference Citation Analysis]
3 Heredia-Torres TG, Rincón-Sánchez AR, Lozano-Sepúlveda SA, Galan-Huerta K, Arellanos-Soto D, García-Hernández M, Garza-Juarez AJ, Rivas-Estilla AM. Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis. Viruses 2022;14. [PMID: 36560766 DOI: 10.3390/v14122762] [Reference Citation Analysis]
4 Tripathi SK, Pal A, Ghosh S, Goel A, Aggarwal R, Banerjee S, Das S. LncRNA NEAT1 regulates HCV-induced Hepatocellular carcinoma by modulating the miR-9-BGH3 axis. J Gen Virol 2022;103. [PMID: 36748628 DOI: 10.1099/jgv.0.001809] [Reference Citation Analysis]
5 Sarantis P, Trifylli E, Koustas E, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors. IJMS 2022;23:13612. [DOI: 10.3390/ijms232113612] [Reference Citation Analysis]
6 Devi P, Engdahl K, Punga T, Bergqvist A. Next-Generation Sequencing Analysis of CpG Methylation of a Tumor Suppressor Gene SHP-1 Promoter in Stable Cell Lines and HCV-Positive Patients. Viruses 2022;14. [PMID: 36366451 DOI: 10.3390/v14112352] [Reference Citation Analysis]
7 Badshah Y, Shabbir M, Khan K, Fatima M, Majoka I, Aslam L, Munawar H. Manipulation of Interleukin-6 (IL-6) and Transforming Growth Factor Beta-1(TGFβ-1) towards viral induced liver cancer pathogenesis. PLoS One 2022;17:e0275834. [PMID: 36215278 DOI: 10.1371/journal.pone.0275834] [Reference Citation Analysis]
8 Talaat RM, Elsayed SS, Abdel-Hakem NE, El-Shenawy SZ. Genetic Polymorphism in Toll-Like Receptor 3 and Interferon Regulatory Factor 3 in Hepatitis C Virus-Infected Patients: Correlation with Liver Cirrhosis. Viral Immunol 2022. [PMID: 36048530 DOI: 10.1089/vim.2022.0058] [Reference Citation Analysis]
9 Hříbek P, Klasová J, Tůma T, Kupsa T, Urbánek P. Etiopathogenetic Factors of Hepatocellular Carcinoma, Overall Survival, and Their Evolution over Time-Czech Tertiary Center Overview. Medicina (Kaunas) 2022;58. [PMID: 36013566 DOI: 10.3390/medicina58081099] [Reference Citation Analysis]
10 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int 2022;42:2029-41. [PMID: 35319165 DOI: 10.1111/liv.15251] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
11 Suhail M, Sohrab SS, Kamal M, Azhar EI. Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview. Front Oncol 2022;12:913231. [DOI: 10.3389/fonc.2022.913231] [Reference Citation Analysis]
12 Merola E, Menotti E, Branz G, Michielan A, Seligmann S, Ratti A, Agugiaro F, Moser L, Vettori G, Franceschini A, Mantovani W, Pertile R, de Pretis G, Pravadelli C. Hepatitis C virus burden: Treating and educating people without prejudice. World J Hepatol 2022;14:1495-503. [PMID: 36158919 DOI: 10.4254/wjh.v14.i7.1495] [Reference Citation Analysis]
13 Tan S, Song X, Zhang C, Sun Y, Zhang J, Zhang Z, Zhang R, Zhang T, Zhu X, Tan H, Wang F. hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/9051229] [Reference Citation Analysis]
14 Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, Mantovani A, Serviddio G, Sacerdoti D. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience. J Dig Dis 2022;23:324-30. [PMID: 35700113 DOI: 10.1111/1751-2980.13103] [Reference Citation Analysis]
15 Wang H, Zhang Y, Zhou J, Li M, Chen Y, Liu Y, Liu H, Ding P, Liang C, Zhu X, Zhang Y, Xin C, Zhang G, Wang A. Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick. Front Cell Infect Microbiol 2022;12:816238. [DOI: 10.3389/fcimb.2022.816238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin Function in Cellular Protein Homeostasis and Human Diseases. Front Cell Dev Biol 2021;9:816214. [PMID: 35111762 DOI: 10.3389/fcell.2021.816214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Badami E, Carcione C, Chinnici CM, Tinnirello R, Conaldi PG, Iannolo G. HCV Interplay With Mir34a: Implications in Hepatocellular Carcinoma. Front Oncol 2022;11:803278. [DOI: 10.3389/fonc.2021.803278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol 2022;2022:5313149. [PMID: 35027925 DOI: 10.1155/2022/5313149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Servin-Rojas M, Tapia-Sosa R, Páez-Zayas VM, Dithurbide-Hernández M, García-Juárez I. Reply to Alexander Ng. Response to Letter to the Editor. Rev Gastroenterol Mex (Engl Ed) 2022:S2255-534X(21)00144-4. [PMID: 34996737 DOI: 10.1016/j.rgmxen.2021.07.007] [Reference Citation Analysis]
20 Russo FP, Zanetto A, Pinto E, Battistella S, Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci 2022;23:500. [PMID: 35008926 DOI: 10.3390/ijms23010500] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
21 Gomez-Quiroz LE, Roman S. Influence of genetic and environmental risk factors in the development of hepatocellular carcinoma in Mexico. Ann Hepatol 2022;27 Suppl 1:100649. [PMID: 34902602 DOI: 10.1016/j.aohep.2021.100649] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
22 Servin-rojas M, Tapia-sosa R, Páez-zayas V, Dithurbide-hernández M, García-juárez I. Respuesta a Alexander Ng. Réplica a la Carta al Editor. Revista de Gastroenterología de México 2022;87:126-127. [DOI: 10.1016/j.rgmx.2021.07.005] [Reference Citation Analysis]
23 Devi P, Ota S, Punga T, Bergqvist A. Hepatitis C Virus Core Protein Down-Regulates Expression of Src-Homology 2 Domain Containing Protein Tyrosine Phosphatase by Modulating Promoter DNA Methylation. Viruses 2021;13:2514. [DOI: 10.3390/v13122514] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Isaac A, El Sakaty TM, Hussein SH, Rasmy HS. Angiopoietin-2 as a predictor of fibrosis regression in chronic hepatitis C virus patients after direct-acting antiviral drugs. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00086-5] [Reference Citation Analysis]
25 Xu J, Hong J, Wang Y, Zhou L, Xu B, Si Y, He Y, Chen Y. Prognostic Influence of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma After Hepatectomy: A Meta-Analysis of Observational Studies. Front Surg 2021;8:769233. [PMID: 34869566 DOI: 10.3389/fsurg.2021.769233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Huang PJ, Chiu CC, Hsiao MH, Yow JL, Tzang BS, Hsu TC. Potential of antiviral drug oseltamivir for the treatment of liver cancer. Int J Oncol 2021;59:109. [PMID: 34859259 DOI: 10.3892/ijo.2021.5289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Váncsa S, Németh D, Hegyi P, Szakács Z, Farkas Á, Kiss S, Hegyi PJ, Kanjo A, Sarlós P, Erőss B, Pár G. Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:744512. [PMID: 34733865 DOI: 10.3389/fmed.2021.744512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, Zhang Z. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Oncol 2021;2021:7764817. [PMID: 34691178 DOI: 10.1155/2021/7764817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sudhindar PD, Wainwright D, Saha S, Howarth R, McCain M, Bury Y, Saha SS, McPherson S, Reeves H, Patel AH, Faulkner GJ, Lunec J, Shukla R. HCV Activates Somatic L1 Retrotransposition-A Potential Hepatocarcinogenesis Pathway. Cancers (Basel) 2021;13:5079. [PMID: 34680227 DOI: 10.3390/cancers13205079] [Reference Citation Analysis]
30 Ramachandran A, Kumar B, Waris G, Everly D. Deubiquitination and Activation of the NLRP3 Inflammasome by UCHL5 in HCV-Infected Cells. Microbiol Spectr 2021;9:e0075521. [PMID: 34431717 DOI: 10.1128/Spectrum.00755-21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Abdelkader NAA, Ahmed OA, Sherief AF, Kandil DM, Gado MS, Al Balakosy AM. Evaluation of long-term changes of aspartate—platelet ratio index, FIB4, and liver stiffness in chronic hepatitis C patients successfully treated by direct-acting antivirals. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00141-4] [Reference Citation Analysis]
32 Valiakou V, Eliadis P, Karamichali E, Tsitsilonis O, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. Int J Mol Sci 2021;22:7961. [PMID: 34360721 DOI: 10.3390/ijms22157961] [Reference Citation Analysis]
33 Zhao P, Malik S, Xing S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front Oncol 2021;11:677926. [PMID: 34336665 DOI: 10.3389/fonc.2021.677926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
34 Brozzetti S, Tancredi M, Bini S, De Lucia C, Antimi J, D'Alterio C, De Sanctis GM, Furlan C, Malpassuti VC, Lucatelli P, Di Martino M, Bezzi M, Ciardi A, Pascale RM. HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers (Basel) 2021;13:3025. [PMID: 34204186 DOI: 10.3390/cancers13123025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
36 Jansons J, Skrastina D, Kurlanda A, Petkov S, Avdoshina D, Kuzmenko Y, Krotova O, Trofimova O, Gordeychuk I, Sominskaya I, Isaguliants M. Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer. Microorganisms 2021;9:1073. [PMID: 34067686 DOI: 10.3390/microorganisms9051073] [Reference Citation Analysis]
37 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
39 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
40 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
41 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
42 Gil-Bazo I. Oncogenes in Cancer: Using the Problem as Part of the Solution. Cancers (Basel) 2020;12:E3373. [PMID: 33202595 DOI: 10.3390/cancers12113373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]